Osiris Therapeutics Receives Title of European Orphan Drug Designation for ProchymalA

Osiris Therapeutics, Inc. , the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that the European Medicines Agency has designated Osiris as the Orphan Drug title holder for ProchymalA .

http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130219005870&newsLang=en&ndmConfigId=1000639&vnsId=41